Usefulness of antiplatelet drugs in ischaemic stroke prevention--update on new trials.
Meta-analysis shows that the absolute risk reduction of antiplatelet therapy for the prevention of fatal and non-fatal stroke is only 1%. This stresses the need for further studies that explore the use of combination therapy and focus on more homogeneous stroke populations such as acute-stroke patients. Recent studies are reviewed that extended the database on antiplatelet drugs in ischaemic stroke prevention.
Rother
Joachim
J
Department of Neurology, Neurological Intensive Care Unit and Stroke Service, Klinikum Minden, Academic Teaching Hospital, Minden, Germany. joachim.roether@klinikum-minden.de
D002545:Brain Ischemia / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D020521:Stroke / Q000517:prevention & control*
D010975:Platelet Aggregation Inhibitors